909 related articles for article (PubMed ID: 19465123)
1. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
[TBL] [Abstract][Full Text] [Related]
2. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
3. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
Shono Y; Jantratid E; Dressman JB
Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
[TBL] [Abstract][Full Text] [Related]
4. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.
Paulson SK; Vaughn MB; Jessen SM; Lawal Y; Gresk CJ; Yan B; Maziasz TJ; Cook CS; Karim A
J Pharmacol Exp Ther; 2001 May; 297(2):638-45. PubMed ID: 11303053
[TBL] [Abstract][Full Text] [Related]
6. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
7. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
8. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
Kambayashi A; Blume H; Dressman JB
Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
10. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.
Jones HM; Parrott N; Ohlenbusch G; Lavé T
Clin Pharmacokinet; 2006; 45(12):1213-26. PubMed ID: 17112297
[TBL] [Abstract][Full Text] [Related]
11. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs.
Tan A; Simovic S; Davey AK; Rades T; Prestidge CA
J Control Release; 2009 Feb; 134(1):62-70. PubMed ID: 19013488
[TBL] [Abstract][Full Text] [Related]
12. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
Jantratid E; De Maio V; Ronda E; Mattavelli V; Vertzoni M; Dressman JB
Eur J Pharm Sci; 2009 Jun; 37(3-4):434-41. PubMed ID: 19491035
[TBL] [Abstract][Full Text] [Related]
13. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
Wei H; Löbenberg R
Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic investigation of the negative food effect of modified release zolpidem.
Andreas CJ; Pepin X; Markopoulos C; Vertzoni M; Reppas C; Dressman JB
Eur J Pharm Sci; 2017 May; 102():284-298. PubMed ID: 28286289
[TBL] [Abstract][Full Text] [Related]
15. The delayed dissolution of paracetamol products in the canine fed stomach can be predicted in vitro but it does not affect the onset of plasma levels.
Kalantzi L; Polentarutti B; Albery T; Laitmer D; Abrahamsson B; Dressman J; Reppas C
Int J Pharm; 2005 May; 296(1-2):87-93. PubMed ID: 15885459
[TBL] [Abstract][Full Text] [Related]
16. Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.
Berlin M; Przyklenk KH; Richtberg A; Baumann W; Dressman JB
Eur J Pharm Biopharm; 2014 Nov; 88(3):795-806. PubMed ID: 25195981
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
18. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
Otsuka K; Wagner C; Selen A; Dressman J
J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
[TBL] [Abstract][Full Text] [Related]
19. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
Gao Y; Carr RA; Spence JK; Wang WW; Turner TM; Lipari JM; Miller JM
Mol Pharm; 2010 Oct; 7(5):1516-26. PubMed ID: 20715778
[TBL] [Abstract][Full Text] [Related]
20. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
